Drug intelligence / Profile preview

ProHeart

Development stage: Unknown
Lead developer: Zoetis
Modality: Small Molecules
Administration: Subcutaneous

Overview

ProHeart is an extended-release injectable veterinary pharmaceutical containing moxidectin, a macrocyclic lactone antiparasitic. It is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment of existing larval and adult hookworm infections (*Ancylostoma caninum* and *Uncinaria stenocephala*) in dogs. The drug is formulated with moxidectin sterile microspheres that slowly release the active ingredient over 6 or 12 months, providing long-lasting protection. It is administered subcutaneously by a veterinarian.

Brand names: ProHeartProHeart 6ProHeart6ProHeart-6ProHeart 12ProHeart12ProHeart-12
Other names: ProHeart 12 (moxidectin)

Targets

δ-GABAAR (Extrasynaptic GABA-A receptor delta-containing subtype)GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on ProHeart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProHeart.

Explore the full profile